Dasatinib and Lung Cancer: Latest Research 2026

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Dasatinib and Lung Cancer: Latest Research 2026

This page summarizes the current state of scientific research on Dasatinib in the context of Lung Cancer as of 2026. The field evolves rapidly — this is a research summary, not medical advice. Consult your oncologist for personalized guidance.

Compound Overview

Dasatinib (Tyrosine Kinase Inhibitor / Senolytic) — FDA-approved for CML and ALL; senolytic use is off-label

Mechanism of action: Src/ABL kinase inhibitor; senolytic (eliminates senescent cells); PDGFR inhibition; anti-inflammatory

Current evidence level: FDA-approved for CML; Mayo Clinic senolytic trials with quercetin; Alzheimer's trial underway

2026 Research Landscape

Direct research on Dasatinib specifically for Lung Cancer remains limited as of 2026, though the mechanistic connections continue to be explored in laboratory settings.

Key areas researchers are currently examining include:

  • Mechanistic studies: Understanding precisely how Dasatinib affects the biological pathways involved in Lung Cancer progression
  • Safety characterization: Defining appropriate doses and monitoring protocols if clinical use is considered
  • Biomarker identification: Finding measurable indicators that could predict which patients might respond
  • Screening studies: Preclinical models are still being used to establish whether clinical investigation is warranted

Where to Find the Most Current Research

To access the latest peer-reviewed publications:

  • PubMed: Search "(Dasatinib[tiab]) AND (Lung Cancer[tiab])" at pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov: Search for active and completed trials with Dasatinib keywords
  • Google Scholar: Sort by date for most recent publications

Research Gaps

The most significant gaps in the Dasatinib + Lung Cancer research landscape as of 2026 include: lack of large Phase III randomized trials, limited long-term safety data in Lung Cancer patients, and absence of biomarker-selected patient populations who might benefit most.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What are the most recent studies on Dasatinib for Lung Cancer?

The most current peer-reviewed studies can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for 'Dasatinib Lung Cancer' filtered to the last 2 years. The current evidence level is: FDA-approved for CML; Mayo Clinic senolytic trials with quercetin; Alzheimer's trial underway.

Are there any 2025-2026 clinical trials for Dasatinib in Lung Cancer?

Check ClinicalTrials.gov with 'Dasatinib' as intervention and 'Lung Cancer' as condition. Filter by 'Recruiting' status for currently enrolling trials. Your oncologist can advise whether any trials may be appropriate for your specific situation.

Has the evidence for Dasatinib in Lung Cancer changed recently?

The field evolves rapidly. The current evidence classification is: FDA-approved for CML; Mayo Clinic senolytic trials with quercetin; Alzheimer's trial underway. For the most up-to-date summary, Insight Swarm generates personalized research reports that incorporate the latest publications specific to your case.